Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Equality Impact Assessment (Guidance development) (PDF 170 KB)

Final appraisal determination

Final appraisal determination document (PDF 295 KB)

Committee papers (PDF 572 KB)

Committee papers presentation slides (PDF 375 KB)

Draft guidance

Appraisal consultation document (PDF 288 KB)

Committee papers (PDF 7.37 MB)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): final scope (post referral) (PDF 108 KB)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): final matrix (post referral) (PDF 101 KB)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): NICE response to scope and matrix (post referral) (PDF 345 KB)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): equality impact assessment (post referral) (PDF 119 KB)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): draft scope for consultation (pre-referral) - January 2015 (PDF 111 KB)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): provisional matrix (pre-referral) - January 2015 (PDF 101 KB)